In conclusion, the results from our study indicate that NET can be considered a well-tolerated and effective alternative for postmenopausal women with ER+/HER2- breast cancer, and that it increases the rates of BCS in both luminal A-like and luminal B-like tumors. Here, ERBB2 is linked to breast cancer.